EUVIMEDEUVIMED entdecken
Crossref

Androsin alleviates non-alcoholic fatty liver disease by activating autophagy and attenuating de novo lipogenesis

Abhinav Singh, Alisha Ansari, Jay Gupta, Himalaya Singh, Kumaravelu Jagavelu, Koneni V Sashidhara

Phytomedicine · 2024

DOI: 10.1016/j.phymed.2024.155702 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2024. Verfasst von Abhinav Singh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacology Division, CSIR-Central Drug Research Institute, Lucknow 226031, UP, India; Academy of Scientific and Innovative Research (AcSIR), Ghazia…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Lipogenesis, Autophagy, Iridoid Glucosides. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease with therapeutic options on the horizon. Picrorhiza kurroa, enriched with iridoid glycosides like picroside I and picroside II is known for its hepatoprotective activity and anti-inflammatory properties. Androsin, the other phytochemical present in P. kurroa has been shown to have anti-inflammatory and anti-asthmatic properties. However, its role in NAFLD is yet to be investigated. PURPOSE: This study aims to identify the potent hepatoprotective agent from P. kurroa that can attenuate NAFLD in HFrD-fed ApoE-/- mice, and elucidate the underlying mechanisms governing its effects. METHODS: Classical purification methods were used to isolate seven compounds, including picroside I, picroside II and androsin from the roots of P. kurroa. NAFLD-induced ApoE-/- mice were administered orally with either picroside I, picroside II, or androsin for 7 weeks. Animals were scanned non-invasively by ultrasonography at 1st and 14th week. Gross histomorphometry was examined by HE and Sirius red staining. mRNA transcript and protein profile associated with autophagy, lipogenesis, inflammation, and fibrosis was done through RT-PCR and Western blot analysis. RESULTS: In-vitro and in-vivo studies revealed that among the seven evaluated compounds, androsin shows the most potent in-vitro activity. Oral dosing of androsin (10 mg/kg) protected the liver against HFrD-induced NAFLD in ApoE-/- mice model. Biochemical analysis revealed a reduction in ALT and AST enzymes and a significant reduction in cholesterol levels. Hepatocyte ballooning, hepatic lipid deposition, inflammation, and fibrosis were reduced. Androsin treatment significantly reduced fibrosis (α-SMA, collagens, TGF-β) and inflammation (ILs, TNF-α, NFκB) in ApoE-/- mice. Mechanistically, androsin activated AMPKα and down-regulated the expression of SREBP-1c, resulting in ameliorating hepatic lipogenesis. CONCLUSION: Our results support autophagy as one of the therapeutic strategies to reduce steatosis and hepatic damage. We found that androsin treatment significantly ameliorated hepatic steatosis, serum lipid levels, and hepatic injury in ApoE-/- induced by HFrD. Androsin administration mitigated lipogenesis by inhibiting SREBP1c/FASN pathway and activating autophagy through AMPKα/PI3K/Beclin1/LC3 pathway.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseLipogenesisAutophagyIridoid GlucosidesAnimalsMaleMiceCinnamatesLiverPicrorhizaHep G2 CellsMice, Inbred C57BLHumans

Stichwörter der Autor:innen

AndrosinApoE-/-NAFLDPicrorhiza kurroaautophagyde novo lipogenesis

Substanzen

Iridoid GlucosidesCinnamatespicroside II

Autor:innen und Institutionen

  • Pharmacology Division, CSIR-Central Drug Research Institute, Lucknow 226031, UP, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, U.P., India.
  • Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Jankipuram Extension, Sitapur Road, Lucknow 226031, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, U.P., I…
  • Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Jankipuram Extension, Sitapur Road, Lucknow 226031, India.
  • Pharmacology Division, CSIR-Central Drug Research Institute, Lucknow 226031, UP, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, U.P., India.. Electronic address: kumaraveluj@cdri.res.in.

Förderung

  • Indian Council of Medical Research

Zitieren

APA

Singh, A., Ansari, A., Gupta, J., Singh, H., Jagavelu, K., & Sashidhara, K. V. (2024). Androsin alleviates non-alcoholic fatty liver disease by activating autophagy and attenuating de novo lipogenesis. Phytomedicine. https://doi.org/10.1016/j.phymed.2024.155702

Vancouver

Singh A, Ansari A, Gupta J, Singh H, Jagavelu K, Sashidhara KV. Androsin alleviates non-alcoholic fatty liver disease by activating autophagy and attenuating de novo lipogenesis. Phytomedicine. 2024. doi:10.1016/j.phymed.2024.155702

BibTeX
@article{Singh2024,
  author = {Singh, Abhinav and Ansari, Alisha and Gupta, Jay and Singh, Himalaya and Jagavelu, Kumaravelu and Sashidhara, Koneni V},
  title = {Androsin alleviates non-alcoholic fatty liver disease by activating autophagy and attenuating de novo lipogenesis},
  journal = {Phytomedicine},
  year = {2024},
  doi = {10.1016/j.phymed.2024.155702}
}
Kostenlos starten →